Supemtek Európai Unió - magyar - EMA (European Medicines Agency)

supemtek

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, emberi - a vakcinák - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

EUCARBON tabletta Magyarország - magyar - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

eucarbon tabletta

f. trenka chem-pharm. fabrik ges.m.b.h. - senna levél; kén; rebarbara; faszén, növényi - contact laxatives

Vidaza Európai Unió - magyar - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidinnel - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - daganatellenes szerek - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Azacitidine Celgene Európai Unió - magyar - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidinnel - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - daganatellenes szerek - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.